Suggested remit: To appraise the clinical and cost effectiveness of leriglitazone within its marketing authorisation for treating adrenoleukodystrophy.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information The topic was considered by the Topic Selection Oversight Panel (TSOP) in September 2023. The panel concluded that the topic should be routed to the Technology Appraisal (TA) work programme. Please see project documents for further details. Following a request from the company, the timelines for the evaluation are to be confirmed.
Process STA Standard
ID number 3903

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
31 October 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
31 October 2023 Topic selection
31 October 2023 Topic selection
31 October 2023 In progress
25 July 2023 - 22 August 2023 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators: 3903
25 July 2023 In progress. Scoping commencing
03 November 2021 (14:00) Scoping workshop
09 September 2021 - 07 October 2021 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
23 September 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of leriglitazone for andrenoleukodystrophy. We have recently invited stakeholders to respond to a written consultation on the draft scope and to attend a scoping workshop for this appraisal. On receiving updated regulatory timing information from the company that is developing leriglitazone, NICE has agreed that holding a scoping exercise at this time would not be appropriate. Consequently, the consultation on the draft scope has closed, and the workshop arranged for Wednesday 03 November 2021 has been cancelled. The scoping exercise will be rescheduled to take place in line with anticipated regulatory approval timings. We apologise for any inconvenience this may cause If you have any comments or concerns, please contact the project manager for this appraisal Emily Richards on 44 (0)161 413 4070 or via email on

For further information on our processes and methods, please see our CHTE processes and methods manual